First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator

Pharmacokinetics, pharmacodynamics, and safety/tolerability of iberdomide (CC‐220), a highly potent oral cereblon E3 ligase modulator (CELMoD), were evaluated in escalating single‐dose (0.03, 0.1, 0.3, 1, 2, 4, 6 mg) and multiple‐dose (0.3 mg once daily for 14 days, 1 mg once daily for 28 days, 0.3...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ying, Gaudy, Allison, Schafer, Peter, Thomas, Michael, Weiss, Daniel, Chen, Nianhang, Liu, Liangang, Xue, Yongjun, Carayannopoulos, Leon, Palmisano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246954/
https://www.ncbi.nlm.nih.gov/pubmed/32969202
http://dx.doi.org/10.1002/cpdd.869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246954/
https://www.ncbi.nlm.nih.gov/pubmed/32969202
http://dx.doi.org/10.1002/cpdd.869

Ejemplares similares